HOME >> BIOLOGY >> NEWS
Cell pathways' SAANDs compounds enhance antitumor effects of Taxol™ in rodent models of breast cancer

HORSHAM, PA (April 3, 2000) -- CP461, a second generation selective apoptotic antineoplastic drug (SAAND) compound, under development by Cell Pathways, Inc. (Nasdaq: CLPA), significantly enhanced the anti-tumor activity of Taxol™ (paclitaxel) in a classic mouse model of human breast cancer, according to a presentation by company scientists this week at the annual meeting of the American Association for Cancer Research (AACR).

Cell Pathways researchers implanted human breast tumor cell lines in immunosuppressed (nude) mice and divided them into treatment and control groups. The treated mice were divided into multiple groups receiving either (1) five days of intravenous paclitaxel alone, (2) 14 days of oral CP461 at a subtherapeutic dose based on previous single agent studies, or (3) the drugs in combination. The researchers then observed the mice for 45 days. The mice tolerated the drug treatments well, whether they received the single agents or combination therapy, and there were no differences in unscheduled deaths or weight loss between the groups. The researchers observed that the reduction in the size of the tumors achieved by the combination of paclitaxel and CP461 was significantly greater (p=0.03) than that achieved with paclitaxel alone during treatment and during the month after discontinuation of treatment.

"This research suggests that CP461, given in combination with paclitaxel, may potentially increase paclitaxel1s efficacy in breast cancer without adding any additional side-effects," said Rifat Pamukcu, M.D., chief scientific officer of Cell Pathways. "CP461 is nearing completion of a Phase Ib safety study as a single agent in cancer patients. Based on these preclinical results, we plan to investigate CP461 as a single agent cancer therapy and in combination cancer chemotherapeutic studies in the near future."

CP461 is a second generation SAAND based on the mechanism of action of Aptosyn (exisulind). Aptosyn™ i
'"/>

Contact: Joan Kureczka
JKureczka@aol.com
415-821-2413
Kureczka/Martin Associates
2-Apr-2000


Page: 1 2

Related biology news :

1. Aptosyn™ (exisulind) and other SAANDs target early event in cancer; AACR presentations detail novel apoptotic pathway
2. Exisulind (Aptosyn™) and other SAANDs compounds halt prostate cancer cell growth by two mechanisms
3. Scientists identify compounds that mimic calorie restriction
4. New, non-radioactive screen for antimalarial compounds
5. Three molecular-targeted compounds show promise against cancers
6. Emory scientists find anti-tumor compounds in magnolia cones
7. Mouse model links alcohol intake to marijuana-like brain compounds
8. Iron-binding compounds decrease body odor
9. New evidence for organic compounds in deep space
10. Researchers identify compounds that might help in spinal cord repair
11. Selected estrogen compounds modify risks of vein clotting, a response to hormone replacement theraphy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/29/2018)... ... August 29, 2018 , ... ... non-invasive technology to identify specific chromosomal abnormalities using morphological assessment through artificial ... and Australia-based Life Whisperer suggests that artificial intelligence (AI) ...
(Date:8/23/2018)... ... August 21, 2018 , ... CRISPR-Cas9 gene ... types and species for the robust functional interrogation of complex biological processes. Gene ... T-cell based immunotherapies, the study of the autoimmunity, the understanding of host-pathogen dynamics ...
(Date:8/21/2018)... ... 21, 2018 , ... Whether it be online or through ... offering customers a successful experience. When browsing the new site in search ... with relevant details such as technical manuals, application notes, and instrument compatibility readily ...
Breaking Biology News(10 mins):
(Date:8/29/2018)... YORBA LINDA, Calif. (PRWEB) , ... August 28, 2018 , ... ... engineers, and scientists from around the world, is proud to announce the launch of ... events LabRoots offers for a chance to win one of LabRoots most popular shirts. ...
(Date:8/26/2018)... , ... August 24, 2018 , ... ... that stem cell-derived exosomes dramatically relieves atopic dermatitis and inhibits a variety of ... According to the paper, the symptoms of mice having severe atopic dermatitis were ...
(Date:8/21/2018)... (PRWEB) , ... August 21, ... ... a software company specializing in medical device compliance and commercialization, has just ... Cockpit® platform. , Written and presented by Dr. Mario Kossmann, ESEP at ...
(Date:8/17/2018)... ... August 16, 2018 , ... KCAS Bioanalytical and Biomarker Services, ... of their team. Dr. Dawn Dufield, Ph.D., joins KCAS as Director of BioPharma. ... group that will specialize in developing quantitative LC-MS/MS assays for biopharma molecules. Dr. ...
Breaking Biology Technology:
Cached News: